Literature DB >> 9720494

Characterization of astroglial versus oligodendroglial phenotypes in glioblastomas by means of quantitative morphonuclear variables generated by computer-assisted microscopy.

C Decaestecker1, I Camby, L Gordower, O Dewitte, P Cras, J J Martin, J L Pasteels, P Van Ham, J Brotchi, R Kiss, I Salmon.   

Abstract

The current WHO classification places glioblastomas in the astrocytoma category. However, whether or not glioblastomas also show oligodendroglial differentiation remains a matter of controversy. This study investigates, at the morphonuclear level, the hypothesis that some glioblastomas (GBMs) may also represent the ultimate level of malignancy in the oligodendroglial lineage. Using a series of 164 GBMs, we sought to ascertain whether any of these GBMs exhibited phenotypical characteristics that were more closely related to oligodendroglial lineages than astrocytic lineages. Phenotypical features were quantitatively determined by means of the computer-assisted microscope analysis of Feulgen-stained nuclei, a process that made it possible to quantitatively describe the patterns of the cell nuclei (and, more specifically, of their chromatin) through 16 variables, and the distribution of the nuclear DNA content (DNA ploidy) through 8 variables. The phenotypical characteristics typical of astrocytic and oligodendroglial tumors were analyzed by means of Discriminant Analysis, a statistical multivariate analysis, performed on a series of 65 astrocytic and oligodendroglial tumors. This series consisted of 14 WHO grade II and 19 grade III astrocytomas and 24 WHO grade II and 8 grade III oligodendrogliomas. This multivariate analysis enabled an accurate model to be produced that distinguished between astrocytomas and oligodendrogliomas on the basis of 5 cytometry-generated variables. This model was used to characterize the phenotype of each of the 164 glioblastomas. The results show that of these 164 glioblastomas, 6 (about 3.5%) displayed phenotypes that were very similar to oligodendrogliomas, and 141 displayed phenotypes that were very similar to astrocytomas. The phenotypes of the 17 remaining GBMs were too ambiguous to be categorized as having a pure astrocytic or oligodendroglial lineage.

Entities:  

Mesh:

Year:  1998        PMID: 9720494     DOI: 10.1097/00005072-199808000-00008

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  7 in total

1.  Oligodendroglial-specific transcriptional factor SOX10 is ubiquitously expressed in human gliomas.

Authors:  Sergei I Bannykh; C Claus Stolt; Jung Kim; Arie Perry; Michael Wegner
Journal:  J Neurooncol       Date:  2006-01       Impact factor: 4.130

2.  Deregulation of the p14ARF/Mdm2/p53 pathway and G1/S transition in two glioblastoma sets.

Authors:  Chiara Ghimenti; Valentina Fiano; Loredana Chiadò-Piat; Adriano Chiò; Paola Cavalla; Davide Schiffer
Journal:  J Neurooncol       Date:  2003-01       Impact factor: 4.130

3.  Glioblastomas with oligodendroglial component-common origin of the different histological parts and genetic subclassification.

Authors:  Barbara Klink; Ben Schlingelhof; Martin Klink; Karen Stout-Weider; Stephan Patt; Evelin Schrock
Journal:  Cell Oncol (Dordr)       Date:  2011-05-03       Impact factor: 6.730

4.  Temozolomide modifies caveolin-1 expression in experimental malignant gliomas in vitro and in vivo.

Authors:  Céline Bruyère; Laurence Abeloos; Delphine Lamoral-Theys; Rebecca Senetta; Véronique Mathieu; Marie Le Mercier; Richard E Kast; Paola Cassoni; Guy Vandenbussche; Robert Kiss; Florence Lefranc
Journal:  Transl Oncol       Date:  2011-04-01       Impact factor: 4.243

5.  Long-term in vitro treatment of human glioblastoma cells with temozolomide increases resistance in vivo through up-regulation of GLUT transporter and aldo-keto reductase enzyme AKR1C expression.

Authors:  Benjamin Le Calvé; Michal Rynkowski; Marie Le Mercier; Céline Bruyère; Caroline Lonez; Thierry Gras; Benjamin Haibe-Kains; Gianluca Bontempi; Christine Decaestecker; Jean-Marie Ruysschaert; Robert Kiss; Florence Lefranc
Journal:  Neoplasia       Date:  2010-09       Impact factor: 5.715

6.  Cerebral glioblastoma with oligodendrogliomal component: analysis of 36 cases.

Authors:  Maurizio Salvati; Anna I Formichella; Alessandro D'Elia; Cristian Brogna; Alessandro Frati; Felice Giangaspero; Roberto Delfini; Antonio Santoro
Journal:  J Neurooncol       Date:  2009-04-03       Impact factor: 4.130

7.  Long-term temozolomide treatment induces marked amino metabolism modifications and an increase in TMZ sensitivity in Hs683 oligodendroglioma cells.

Authors:  Delphine Lamoral-Theys; Marie Le Mercier; Benjamin Le Calvé; Michal A Rynkowski; Céline Bruyère; Christine Decaestecker; Benjamin Haibe-Kains; Gianluca Bontempi; Jacques Dubois; Florence Lefranc; Robert Kiss
Journal:  Neoplasia       Date:  2010-01       Impact factor: 5.715

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.